Related Experiment Video
Updated: Mar 14, 2026
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Recycling senescent cell lipids for targeted senotherapy
Xiaoxiao Ji1,2,3,4, Xingzi He1,2,3,4, Honglu Cai1,2,3,4
1Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Abstract:
Senescent cells (SnCs) are increasingly recognized as key contributors to osteoarthritis, with conventional strategies centered on their elimination. However, senolytic approaches face mounting limitations, driving the need for refined interventions. Here, we exploit SnCs' lipid metabolic signature to develop a senotherapeutic strategy. Given the universal lipid accumulation in SnCs and the dual role of lipids as both metabolic liabilities and essential lubricants, we engineer an injectable nanoliposuction hydrogel platform designed for "waste recycling". This system removes excess lipids to mitigate senescence-associated secretory phenotype (SASP) propagation and incorporates the harvested lipids as a pivotal component of the biomimetic lubricating system, thereby alleviating mechanical allodynia and cartilage wear. This strategy circumvents potential side effects associated with direct SnCs clearance and repurposes these traditionally harmful cells as functional resources. Our findings establish a shift in the philosophy of senescence therapy, transitioning the focus from destructive ablation to spatially adaptive reallocation of metabolites.
Insights
Senescent cells in osteoarthritis are targeted by a novel hydrogel that recycles their accumulated lipids. This approach reduces harmful secretions and enhances joint lubrication, offering a new therapeutic strategy.
Area of Science:
- Biomedical Engineering
- Osteoarthritis Research
- Cellular Senescence
Background:
- Senescent cells (SnCs) contribute to osteoarthritis (OA) pathogenesis.
- Conventional senolytic strategies for OA face limitations.
- SnCs exhibit unique lipid metabolic signatures.
Purpose of the Study:
- To develop a novel senotherapeutic strategy targeting the lipid metabolism of SnCs in OA.
- To engineer an injectable nanoliposuction hydrogel platform for lipid management in OA.
Main Methods:
- Development of an injectable nanoliposuction hydrogel.
- Exploitation of SnCs' lipid accumulation for therapeutic benefit.
- Integration of harvested lipids into a biomimetic lubricating system.
Main Results:
- The hydrogel platform effectively removes excess lipids from SnCs.
- Lipid removal mitigates the senescence-associated secretory phenotype (SASP).
- Incorporated lipids improved joint lubrication, alleviating mechanical allodynia and cartilage wear.
Conclusions:
- This strategy offers a novel approach to OA therapy by repurposing SnCs' lipids.
- The nanoliposuction hydrogel provides a senotherapeutic intervention with reduced side effects.
- Findings shift OA senescence therapy from ablation to metabolite reallocation.
More Related Videos
13:59A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence
Published on: August 12, 2018
10:39Author Spotlight: Improved Lipofuscin Models and Quantification of Outer Segment Phagocytosis Capacity in Highly Polarized Human Retinal Pigment Epithelial Cultures
Published on: April 14, 2023
